Introduction:
Initiation of construction for Lek's advanced biopharmaceutical production center in Lendava is underway
Features:
The construction will occur on Lek's existing site in Lendava and involves three planned facilities.
The facility's primary objectives include generating energy products for current production demands and facilitating future drug substance production, particularly for biosimilars.
The combined surface area of the three facilities will be 40,000 m2.
The project will create 330 new jobs, contributing to the advancement of the pharmaceutical industry in the Pomurje region.
Biosimilars play a crucial role in saving costs and enhancing the sustainability of healthcare systems.
Biopharmaceutical production demands high purity standards with minimal environmental impact.
The center incorporates the best available technology to reduce energy consumption and resource use.
The expansion of Lek's biosimilar portfolio is a response to the growing demand for accessible treatments in Europe.
The center is designed to include state-of-the-art production and storage facilities and is expected to be operational by the end of 2026.
Specifications:
Name Lek's
Type Construction
Year 2026
